Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference By: Compass Therapeutics, Inc. via Business Wire January 07, 2022 at 09:00 AM EST Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that Thomas Schuetz, M.D., Ph.D., Co-founder and Chief Executive Officer, will present a company update at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022. The presentation details are: Date: Wednesday, January 12, 2022 Time: 8:15 – 8:55 a.m. ET Location: Virtual – please refer to the Investor tab on the Compass website which will be updated as details for the webcast link becomes available. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’ scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information on Compass, please visit the company’s website at: www.compasstherapeutics.com View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005965/en/Contacts Investor Contact Vered Bisker-Leib, President & Chief Operating Officer ir@compasstherapeutics.com Media Contact Anna Gifford, Communications Manager media@compasstherapeutics.com 617-500-8099 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference By: Compass Therapeutics, Inc. via Business Wire January 07, 2022 at 09:00 AM EST Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that Thomas Schuetz, M.D., Ph.D., Co-founder and Chief Executive Officer, will present a company update at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022. The presentation details are: Date: Wednesday, January 12, 2022 Time: 8:15 – 8:55 a.m. ET Location: Virtual – please refer to the Investor tab on the Compass website which will be updated as details for the webcast link becomes available. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’ scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information on Compass, please visit the company’s website at: www.compasstherapeutics.com View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005965/en/Contacts Investor Contact Vered Bisker-Leib, President & Chief Operating Officer ir@compasstherapeutics.com Media Contact Anna Gifford, Communications Manager media@compasstherapeutics.com 617-500-8099
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that Thomas Schuetz, M.D., Ph.D., Co-founder and Chief Executive Officer, will present a company update at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022. The presentation details are: Date: Wednesday, January 12, 2022 Time: 8:15 – 8:55 a.m. ET Location: Virtual – please refer to the Investor tab on the Compass website which will be updated as details for the webcast link becomes available. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’ scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information on Compass, please visit the company’s website at: www.compasstherapeutics.com View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005965/en/
Investor Contact Vered Bisker-Leib, President & Chief Operating Officer ir@compasstherapeutics.com Media Contact Anna Gifford, Communications Manager media@compasstherapeutics.com 617-500-8099